NO20015447L - Kinolinderivater som inhibitorer av MEK enzymer - Google Patents
Kinolinderivater som inhibitorer av MEK enzymerInfo
- Publication number
- NO20015447L NO20015447L NO20015447A NO20015447A NO20015447L NO 20015447 L NO20015447 L NO 20015447L NO 20015447 A NO20015447 A NO 20015447A NO 20015447 A NO20015447 A NO 20015447A NO 20015447 L NO20015447 L NO 20015447L
- Authority
- NO
- Norway
- Prior art keywords
- carbon atoms
- optionally
- pyrimidinyl
- pyridinyl
- alkyl
- Prior art date
Links
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000004076 pyridyl group Chemical group 0.000 abstract 4
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000000962 organic group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9910580.1A GB9910580D0 (en) | 1999-05-08 | 1999-05-08 | Chemical compounds |
| PCT/GB2000/001698 WO2000068199A1 (en) | 1999-05-08 | 2000-05-03 | Quinoline derivatives as inhibitors of mek enzymes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20015447D0 NO20015447D0 (no) | 2001-11-07 |
| NO20015447L true NO20015447L (no) | 2001-12-12 |
Family
ID=10852989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20015447A NO20015447L (no) | 1999-05-08 | 2001-11-07 | Kinolinderivater som inhibitorer av MEK enzymer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6638945B1 (no) |
| EP (1) | EP1178965B1 (no) |
| JP (1) | JP2002544194A (no) |
| KR (1) | KR20020000803A (no) |
| CN (1) | CN1350524A (no) |
| AT (1) | ATE250582T1 (no) |
| AU (1) | AU4589200A (no) |
| BR (1) | BR0010366A (no) |
| CA (1) | CA2371469A1 (no) |
| DE (1) | DE60005504T2 (no) |
| GB (1) | GB9910580D0 (no) |
| IL (1) | IL146319A0 (no) |
| NO (1) | NO20015447L (no) |
| TR (1) | TR200103185T2 (no) |
| WO (1) | WO2000068199A1 (no) |
| ZA (1) | ZA200108969B (no) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8856201A (en) | 2000-09-01 | 2002-03-13 | Andel Inst Van | Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
| EP1337513A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | 4-substituted quinolines as antitumor agents |
| US7067532B2 (en) | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
| US6603005B2 (en) | 2000-11-15 | 2003-08-05 | Aventis Pharma S.A. | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them |
| US6602884B2 (en) | 2001-03-13 | 2003-08-05 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them |
| WO2002076496A1 (en) * | 2001-03-22 | 2002-10-03 | Van Andel Institute | Anthrax lethal factor inhibits tumor growth and angiogenesis |
| GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| GB0215823D0 (en) * | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| GB0225579D0 (en) | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| EP1633718B1 (en) * | 2003-06-17 | 2012-06-06 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s |
| PL2392565T3 (pl) * | 2003-09-26 | 2014-08-29 | Exelixis Inc | Modulatory c-Met i sposoby stosowania |
| US20090239936A1 (en) | 2006-05-15 | 2009-09-24 | Yoshikazu Sugimoto | Prophylactic and Therapeutic Agent for Cancer |
| WO2008139288A2 (en) * | 2007-05-09 | 2008-11-20 | Pfizer Inc. | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials |
| TW201920110A (zh) | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
| CN102625799A (zh) * | 2009-06-25 | 2012-08-01 | 安姆根有限公司 | 杂环化合物及其用途 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| CA2806734A1 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| EP2598660B1 (en) | 2010-07-26 | 2017-03-15 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| EP3249054A1 (en) | 2012-12-20 | 2017-11-29 | Biomatrica, INC. | Formulations and methods for stabilizing pcr reagents |
| AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
| CN105189462B (zh) | 2013-02-20 | 2017-11-10 | 卡拉制药公司 | 治疗性化合物和其用途 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| CN105491883B (zh) | 2013-06-13 | 2018-11-02 | 生物马特里卡公司 | 细胞稳定化 |
| AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| ES2891555T3 (es) | 2014-06-10 | 2022-01-28 | Biomatrica Inc | Estabilización de trombocitos a temperaturas ambiente |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| CN108473435A (zh) | 2015-10-05 | 2018-08-31 | 纽约市哥伦比亚大学理事会 | 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗 |
| KR102589056B1 (ko) | 2015-12-08 | 2023-10-12 | 바이오매트리카 인코포레이티드 | 적혈구 침강 속도의 감소 |
| CN106220560A (zh) * | 2016-07-27 | 2016-12-14 | 华侨大学 | 一种多取代喹啉衍生物的制备方法 |
| EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| CN109688818A (zh) | 2016-09-08 | 2019-04-26 | 卡拉制药公司 | 治疗化合物的晶型及其用途 |
| CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR20230081932A (ko) | 2021-11-30 | 2023-06-08 | 주식회사 메타뷰 | 실내 위치 측위 정보를 모니터링하는 고온환경 스마트 팩토리 안전관리 시스템 및 그 방법 |
| KR102557537B1 (ko) | 2022-08-25 | 2023-07-20 | 김형미 | 개선된 통신 방식을 활용한 스마트 도어 제어 방법, 장치 및 시스템 |
| KR102498884B1 (ko) | 2022-11-04 | 2023-02-10 | 주식회사 레딕스 | 현장 작업자와 화물차 기사의 안전관리를 위한 안전관리 시스템 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE317376B (no) | 1961-07-10 | 1969-11-17 | Roussel Uclaf | |
| FR2077455A1 (en) | 1969-09-03 | 1971-10-29 | Aries Robert | 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials |
| US3936461A (en) | 1973-09-24 | 1976-02-03 | Warner-Lambert Company | Substituted 4-benzylquinolines |
| FR2498187A1 (fr) | 1981-01-16 | 1982-07-23 | Rhone Poulenc Sante | Procede de preparation d'amino-4 chloro-7 quinoleines |
| IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| DE69222637T2 (de) | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP0597003A1 (en) | 1991-08-02 | 1994-05-18 | Pfizer Inc. | Quinoline derivatives as immunostimulants |
| US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| DE69622183D1 (de) | 1995-11-07 | 2002-08-08 | Kirin Brewery | Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen |
| PT912559E (pt) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
| EP0929526B1 (en) * | 1996-09-25 | 2005-07-27 | AstraZeneca AB | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| EP0993437B1 (en) * | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| HUP0003731A3 (en) | 1997-07-01 | 2002-11-28 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| KR100705142B1 (ko) | 1998-09-29 | 2007-04-06 | 와이어쓰 홀딩스 코포레이션 | 단백질 티로신 키나제 억제제로서 치환 3-시아노퀴놀린 |
| EP1950201A1 (en) | 1998-09-29 | 2008-07-30 | Wyeth Holdings Corporation | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
-
1999
- 1999-05-08 GB GBGB9910580.1A patent/GB9910580D0/en not_active Ceased
-
2000
- 2000-05-03 CN CN00807302A patent/CN1350524A/zh active Pending
- 2000-05-03 AU AU45892/00A patent/AU4589200A/en not_active Abandoned
- 2000-05-03 BR BR0010366-7A patent/BR0010366A/pt not_active IP Right Cessation
- 2000-05-03 EP EP00927492A patent/EP1178965B1/en not_active Expired - Lifetime
- 2000-05-03 WO PCT/GB2000/001698 patent/WO2000068199A1/en not_active Ceased
- 2000-05-03 US US09/959,434 patent/US6638945B1/en not_active Expired - Fee Related
- 2000-05-03 IL IL14631900A patent/IL146319A0/xx unknown
- 2000-05-03 JP JP2000617179A patent/JP2002544194A/ja active Pending
- 2000-05-03 DE DE60005504T patent/DE60005504T2/de not_active Expired - Fee Related
- 2000-05-03 KR KR1020017014194A patent/KR20020000803A/ko not_active Withdrawn
- 2000-05-03 AT AT00927492T patent/ATE250582T1/de not_active IP Right Cessation
- 2000-05-03 TR TR2001/03185T patent/TR200103185T2/xx unknown
- 2000-05-03 CA CA002371469A patent/CA2371469A1/en not_active Abandoned
-
2001
- 2001-10-30 ZA ZA200108969A patent/ZA200108969B/en unknown
- 2001-11-07 NO NO20015447A patent/NO20015447L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1350524A (zh) | 2002-05-22 |
| ZA200108969B (en) | 2003-01-30 |
| EP1178965B1 (en) | 2003-09-24 |
| KR20020000803A (ko) | 2002-01-05 |
| TR200103185T2 (tr) | 2002-05-21 |
| ATE250582T1 (de) | 2003-10-15 |
| AU4589200A (en) | 2000-11-21 |
| IL146319A0 (en) | 2002-07-25 |
| DE60005504T2 (de) | 2004-06-24 |
| EP1178965A1 (en) | 2002-02-13 |
| JP2002544194A (ja) | 2002-12-24 |
| GB9910580D0 (en) | 1999-07-07 |
| BR0010366A (pt) | 2002-02-13 |
| WO2000068199A1 (en) | 2000-11-16 |
| US6638945B1 (en) | 2003-10-28 |
| CA2371469A1 (en) | 2000-11-16 |
| DE60005504D1 (de) | 2003-10-30 |
| NO20015447D0 (no) | 2001-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20015447D0 (no) | Kinolinderivater som inhibitorer av MEK enzymer | |
| NO20015446D0 (no) | Kinolin-derivater som inhibitorer for MEK-enzymer | |
| NO20015448D0 (no) | Kinolinderivater som inhibitorer av MEK enzymer | |
| HUP0104816A2 (hu) | 3-Azabiciklo[3.1.0]hexán-származékok mint ópiát receptor ligandumok és eljárás előállításukra | |
| NO2015020I2 (no) | Ceritinib eller et farmasøytisk akseptabelt salt derav | |
| EA200000731A1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
| FI915970A0 (fi) | Laekemedel, som aer nyttiga vid vaord av cancer och som har antihistaminegenskaper. | |
| DE3462504D1 (de) | Indole-3-carboxamide derivatives | |
| NO163855C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive arylcyklobutylalkylaminer. | |
| NO171786C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater | |
| AU676348B2 (en) | New 2(1H)-quinolone compounds, process for their preparationand the pharmaceutical compositions which contain them | |
| SE8800863L (sv) | 3-(2-haloalkyl)-1,4-oxatiiner och 2-(2-haloalkyl)1,4-ditiiner och bahandling av leukemi och tumoerer daermed | |
| JO1676B1 (en) | Extra compounds indinol II | |
| HUP0001727A2 (hu) | Új 1-aza-2-alkil-6-aril-cikloalkán-származékok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények | |
| DE69301639D1 (de) | Tetrahydronaphtalenderivate, ihre Herstellung und ihre therapeutische Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |